Medicenna Therapeutics Investor Update

Medicenna Therapeutics (NASDAQ/TSX: MDNA) Investor Update

Adelaide Capital

Medicenna Investor Update

Stock Therapy with Penny Queen

Is Medicenna Therapeutics Closing in on a Cure for Cancer?

Stock Therapy with Penny Queen

🔴 Medicenna Therapeutics Corp MDNA Stock Trading Facts 🔴

Stuff About Stocks

Medicenna Therapeutics completes Phase 2B study on cancer drug mdna55

Proactive Investors

BIG TRADING UPSIDE : MDNAF STOCK ANALYSIS | MEDICENNA THERAPEUTICS STOCK

SATYAJIT DASGUPTA

Medicenna Therapeutics - Corporate Update by CEO, Fahar Merchant and CFO, Elizabeth Williams

San Diego Torrey Hills Capital

Medicenna Intro Interview Plus Impressive Cancer Treatment Data

Stock Therapy with Penny Queen

Medicenna Presentation Q4 2022 Investor Presentation with CEO Fahar Merchant PhD

Stock Therapy with Penny Queen

Biotech funding has been an issue in the pharmaceutical industry, says Novo Holdings partner

CNBC International News

December 2024 Investor Webinar

Cynata Therapeutics

Fahar Merchant, President and CEO of Medicenna: Amendment Means Clinical Trial Changes

Looking at cancer as a species not a disease - Medicenna Therapeutics Corp. | Healthtech Insights

Medicenna Therapeutics Corp. (TSX: MDNA) (OTCQB: MDNAF) | Stock News Now

Planet MicroCap

Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval

Synairgen CEO on funding critical Phase 2 trial for SNG001

Proactive Investors

Targeting and treating cancer in three different ways through Medicenna’s MDNA55

Viking Therapeutics: The Next Millionaire-Maker Biotech Stock To Invest In?

Stocks Telegraph

CEO Talks with Fahar Merchant, CEO & President of Medicenna Therapeutics Inc.

FocusLearningToronto